Pin1 Inhibitors Target Oncogenic Pathways in Cancer
Solution Overview
Problem
Current treatments for immune disorders and cancers are inadequate due to side effects and limited effectiveness, and there is a need for therapeutic agents that can inhibit Pin1, a protein overexpressed in various cancers, to suppress oncogenic pathways.
Innovation Solution
Development of compositions and methods to inhibit Pin1 by administering specific compounds, known as Table 1 Compounds, which can be used to treat immune disorders and proliferative disorders by reducing Pin1 expression levels, thereby targeting multiple oncogenic pathways simultaneously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunosuppressive agents are used to treat immune disorders, then the immune response can be suppressed, but adverse side effects occur and effectiveness varies
Solution Approach 1:
The patent changes the molecular target parameter from general immune suppression to specific Pin1 protein inhibition. The compounds of Table 1 are designed to selectively bind to and inhibit Pin1, which is overexpressed in cancer cells and certain immune disorders, thereby achieving treatment effectiveness while reducing adverse side effects associated with non-specific immunosuppression.
2Reliability
If Pin1 is overexpressed in cancers, then oncogenic pathways are activated, but current cancer treatments cannot reliably target this mechanism
Solution Approach 1:
The patent extracts and isolates the Pin1 protein as a specific therapeutic target from the complex network of oncogenic pathways. By developing compounds that specifically inhibit Pin1, the invention simplifies the treatment approach to focus on one critical driver protein that controls multiple oncogenic pathways, thereby improving treatment reliability without needing to address every possible cancer mechanism.
Solution Approach 2:
The patent identifies Pin1 as a universal regulator that controls multiple oncogenic pathways simultaneously. The Pin1 inhibitor compounds can therefore address diverse cancer types and mechanisms through a single target, providing multi-functional therapeutic effect that simplifies the complexity of cancer treatment.
3Reliability
If Pin1 inhibitor compounds are developed to target multiple oncogenic pathways, then cancer treatment effectiveness improves, but the complexity of compound development increases
Solution Approach 1:
The patent segments the complex task of cancer treatment into targeting a single specific protein (Pin1) with multiple specific compounds (Table 1). This segmentation allows for systematic development and optimization of inhibitors against one target, making the manufacturing and clinical development process more manageable compared to addressing multiple cancer targets simultaneously.
Data Source
AI summary
The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.